These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10901349)

  • 1. Bupropion-tranylcypromine combination for treatment-refractory depression.
    Pierre JM; Gitlin MJ
    J Clin Psychiatry; 2000 Jun; 61(6):450-1. PubMed ID: 10901349
    [No Abstract]   [Full Text] [Related]  

  • 2. Tranylcypromine plus risperidone for treatment-refractory major depression.
    Stoll AL; Haura G
    J Clin Psychopharmacol; 2000 Aug; 20(4):495-6. PubMed ID: 10917417
    [No Abstract]   [Full Text] [Related]  

  • 3. Tranylcypromine treatment of major depression.
    Liebowitz MR
    J Clin Psychiatry; 1987 Jul; 48(7):303. PubMed ID: 3597337
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants.
    Nolen WA; Haffmans PM; Bouvy PF; Duivenvoorden HJ
    J Affect Disord; 1993 Jul; 28(3):189-97. PubMed ID: 8408980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with low doses of tranylcypromine resulted in a disappointing remission rate.
    Nolen WA; van den Broek WW; Birkenhäger TK
    Am J Psychiatry; 2007 Mar; 164(3):524; author reply 524. PubMed ID: 17329480
    [No Abstract]   [Full Text] [Related]  

  • 6. Paroxetine/bupropion combination treatment for refractory depression.
    Marshall RD; Liebowitz MR
    J Clin Psychopharmacol; 1996 Feb; 16(1):80-1. PubMed ID: 8834426
    [No Abstract]   [Full Text] [Related]  

  • 7. Tranylcypromine and bupropion combination therapy in treatment-resistant major depression: a report of 2 cases.
    Quante A; Zeugmann S
    J Clin Psychopharmacol; 2012 Aug; 32(4):572-4. PubMed ID: 22760351
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients.
    Birkenhäger TK; van den Broek WW; Mulder PG; Bruijn JA; Moleman P
    J Clin Psychiatry; 2004 Nov; 65(11):1505-10. PubMed ID: 15554763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAO inhibition as antidepressive mechanism reevaluated. A controlled study with tranylcypromine isomers.
    Beckmann H; Moises HW
    Mod Probl Pharmacopsychiatry; 1983; 19():211-4. PubMed ID: 6865965
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
    Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
    Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine oxidase inhibitors revisited: what you should know.
    Goldberg JF; Thase ME
    J Clin Psychiatry; 2013 Feb; 74(2):189-91. PubMed ID: 23473352
    [No Abstract]   [Full Text] [Related]  

  • 13. Monoamine Oxidase Inhibition in a Patient With Type 1 Diabetes and Depression.
    Emory H; Mizrahi N
    J Diabetes Sci Technol; 2016 Sep; 10(5):1203-4. PubMed ID: 26961977
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of lithium-tranylcypromine treatment in refractory depression.
    Price LH; Charney DS; Heninger GR
    Am J Psychiatry; 1985 May; 142(5):619-23. PubMed ID: 3920923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monoamine oxidase inhibitors in the treatment of obsessive disorders. Two case reports and review of the literature].
    Erfurth A; Schmauss M
    Nervenarzt; 1993 Jan; 64(1):70-2. PubMed ID: 8437650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole augmentation of tranylcypromine in treatment-resistant major depression.
    Goforth HW; Carroll BT
    J Clin Psychopharmacol; 2007 Apr; 27(2):216-7. PubMed ID: 17414252
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.
    Feighner JP; Herbstein J; Damlouji N
    J Clin Psychiatry; 1985 Jun; 46(6):206-9. PubMed ID: 3997787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute exacerbation of depression after discontinuation of monoamine oxidase inhibitor prior to cardiac surgery.
    Abdi S; Fishman SM; Messner E
    Anesth Analg; 1996 Sep; 83(3):656-7. PubMed ID: 8780301
    [No Abstract]   [Full Text] [Related]  

  • 19. STAR*D level IV methodology.
    Wingo AP; Ghaemi SN
    Am J Psychiatry; 2007 Apr; 164(4):681; author reply 681. PubMed ID: 17403987
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination therapy in the treatment of major depressive disorder complicated by fibromyalgia and menopause.
    Clayton AH; Kaltsounis-Puckett J
    Psychosomatics; 2002; 43(6):491-3. PubMed ID: 12444233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.